Comparative Pharmacology
Head-to-head clinical analysis: NITRO BID versus NITROGLYCERIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITRO BID versus NITROGLYCERIN.
NITRO-BID vs NITROGLYCERIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.
Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing cGMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.
Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.
None Documented
Clinical Note
moderateNitroglycerin + Etacrynic acid
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid."
Clinical Note
moderateNitroglycerin + Bumetanide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bumetanide."
Clinical Note
moderateNitroglycerin + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydrochlorothiazide."
Clinical Note
moderateNone Documented
Terminal half-life of nitroglycerin is 1-4 minutes; clinical effects are short-lived due to rapid redistribution and metabolism.
Terminal half-life: 1–4 minutes for the parent compound; clinical effects dissipate within the same time frame, correlating with rapid metabolism.
Renal: <1% unchanged; extensive metabolism followed by renal excretion of metabolites, with minor biliary/fecal elimination (<5%).
Metabolized extensively by hepatic glutathione-organic nitrate reductase and other non-specific esterases; renal excretion of metabolites accounts for approximately 50%, with fecal elimination of about 20-30%. Less than 1% of unchanged drug is excreted renally.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator
Nitroglycerin + Indapamide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Indapamide."